Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Fusion Antibodies stock price, quote, forecast and news

FAB.L
GB00BDQZGK16

Price

0
Today +/-
-0
Today %
-0 %
P

Fusion Antibodies stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Fusion Antibodies stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Fusion Antibodies stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Fusion Antibodies stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Fusion Antibodies's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Fusion Antibodies Stock Price History

DateFusion Antibodies Price
9/6/20240 undefined
9/5/20240 undefined
9/4/20240 undefined
9/3/20240 undefined
9/2/20240 undefined
8/30/20240 undefined
8/29/20240 undefined
8/28/20240 undefined
8/27/20240 undefined
8/23/20240 undefined
8/22/20240 undefined
8/21/20240 undefined
8/20/20240 undefined
8/19/20240 undefined
8/16/20240 undefined
8/15/20240 undefined
8/14/20240 undefined
8/13/20240 undefined
8/12/20240 undefined

Fusion Antibodies Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Fusion Antibodies, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Fusion Antibodies from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Fusion Antibodies’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Fusion Antibodies. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Fusion Antibodies’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Fusion Antibodies’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Fusion Antibodies’s growth potential.

Fusion Antibodies Revenue, EBIT and net profit per share

DateFusion Antibodies RevenueFusion Antibodies EBITFusion Antibodies Net Income
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined

Fusion Antibodies Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (k)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2015201620172018201920202021202220232024e2025e
01122344216
---100.00-50.0033.33--50.00-50.00500.00
---50.00-33.3350.0050.00---
00010122000
0000-1-1-1-1-2-10
-----50.00-33.33-25.00-25.00-100.00-100.00-
01,00000-1,0000-2,000-1,000-2,000-3,0000
--------50.00100.0050.00-
22.0922.0922.0916.1222.0922.0925.4625.9526.0100
-----------
Details

Keystats

ⓘ

Revenue and Growth

The Fusion Antibodies Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Fusion Antibodies is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (k)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (k)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (k)PROVISIONS (k)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (k)DEBT (M)TOTAL CAPITAL (M)
201520162017201820192020202120222023
                 
0.10.410.294.491.981.542.692.050.2
0.170.240.510.511.060.540.590.780.36
35.388.5451.79140.2622.6587189248335
0070.2681.82242.67340480585539
25.9527.4312.24281.990297758624258
0.330.690.935.513.312.84.714.281.69
0.040.050.110.551.591.471.120.630.38
000000000
000000189248335
00006.214200
000000000
01.131.121.161.341.76000
0.041.181.231.72.943.241.310.880.71
0.371.872.167.216.246.046.025.162.4
                 
0.550.550.550.880.880.881.021.041.04
6.166.166.164.874.874.877.557.657.65
-6,539.63-5,251.91-5,003819.09-401.88-944-3,824-5,003-7,564
000000000
000000000
0.171.461.716.585.354.814.753.681.12
143.9298.4245.63281.28729.36415344466480
31.51287.65167.9239.360391444629313
6.245.3816.6815.65022454751
000000000
00033.7666.541611636635
0.180.390.430.570.80.9911.210.88
00043.5372.6421967340
000000000
202020202020202020
20202063.5392.64239872360
0.20.410.450.630.891.231.081.230.94
0.371.872.167.216.246.045.834.922.06
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Fusion Antibodies provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Fusion Antibodies's financial health and stability.

Assets

Fusion Antibodies's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Fusion Antibodies must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Fusion Antibodies after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Fusion Antibodies's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (k)DEPRECIATION (M)DEFERRED TAXES (k)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (k)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201520162017201820192020202120222023
01,00000-1,0000-2,000-1,000-2,000
000000000
0000001,00000
000000000
0000001,00000
000000000
000000000
0000-10-10-1
0000-10000
0000-10000
000000000
000000000
000000000
000400200
000400200
---------
000000000
0004-2010-1
-0.190.31-0.13-0.37-2.48-0.27-1.5-0.58-1.87
000000000

Fusion Antibodies stock margins

The Fusion Antibodies margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Fusion Antibodies. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Fusion Antibodies.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Fusion Antibodies's sales revenue. A higher gross margin percentage indicates that the Fusion Antibodies retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Fusion Antibodies's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Fusion Antibodies's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Fusion Antibodies's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Fusion Antibodies. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Fusion Antibodies's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Fusion Antibodies Margin History

Fusion Antibodies Gross marginFusion Antibodies Profit marginFusion Antibodies EBIT marginFusion Antibodies Profit margin
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %

Fusion Antibodies Stock Sales Revenue, EBIT, Earnings per Share

The Fusion Antibodies earnings per share therefore indicates how much revenue Fusion Antibodies has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Fusion Antibodies earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Fusion Antibodies's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Fusion Antibodies’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Fusion Antibodies's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Fusion Antibodies Revenue, EBIT and net profit per share

DateFusion Antibodies Sales per ShareFusion Antibodies EBIT per shareFusion Antibodies Earnings per Share
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined

Fusion Antibodies business model

The company Fusion Antibodies PLC is a biotechnology company specializing in the production of antibodies for medical and scientific research. The company, based in Belfast, Northern Ireland, was founded in 2001 and has been listed on the London Stock Exchange since 2017. Fusion Antibodies' business model is based on the development of customized antibodies for customers in the pharmaceutical, biotech, diagnostics, and academic research sectors. The company offers a wide range of services throughout the entire antibody development process, from antigen design to the production of recombinant antibodies and antibody conjugates. Fusion Antibodies divides its business operations into three main departments: antibody engineering, antibody production, and antibody conjugation. The antibody engineering department is involved in the discovery and optimization of antibodies using advanced technologies such as phage display and hybridoma technologies. In the antibody production department, the desired antibodies are produced through cell culture or recombinant technologies. Finally, in the antibody conjugation department, the antibody is coupled with other molecules such as enzymes, toxins, or fluorescent dyes to generate new therapeutic agents or diagnostic systems. Fusion Antibodies also offers a variety of products that can be either individually configured by customers or purchased as standard products. The portfolio of standard products includes antibodies against known target molecules such as GFP, His-tag, and HA-tag, as well as antibodies tailored to specific applications such as anti-idiotypic antibodies or antibodies for the detection of posttranslational modifications of proteins. In addition, Fusion Antibodies also offers a customized service for the production of antibodies against customer-specific target molecules, tailored to the individual needs of the customer. Fusion Antibodies has numerous customers from the biopharmaceutical and biotechnology industry, as well as from academic research. The company works closely with its customers to meet their specific requirements and offers flexibility and a creative approach through its technology platform in developing solutions for their challenges. The company has a strong R&D department and continuously invests in the development of new technologies and products to maintain and expand its competitiveness. Fusion Antibodies also has partnerships with other companies and institutions in the biotech industry to jointly develop new technologies and products. Overall, Fusion Antibodies is an innovative company specializing in the development of antibodies for use in medical and scientific research. Through its wide range of services, products, and partnerships, the company has solidified its position in the biotech industry and is expected to continue to play an important role in the development of new therapeutic and diagnostic approaches. Fusion Antibodies is one of the most popular companies on Eulerpool.com.

Fusion Antibodies SWOT Analysis

Strengths

Fusion Antibodies PLC has several strengths that give the company a competitive advantage:

  • Strong technical expertise in antibody discovery and engineering.
  • Well-established relationships with major pharmaceutical companies.
  • Experienced and dedicated research and development team.
  • Access to state-of-the-art technology and laboratory facilities.
  • Proven track record of successful antibody development projects.

Weaknesses

Despite its strengths, Fusion Antibodies PLC also faces some weaknesses:

  • Relatively small size compared to some competitors, limiting resources and scalability.
  • Dependent on a limited number of key clients for a significant portion of revenue.
  • Limited geographic presence, potentially missing out on opportunities in other markets.
  • Highly regulated industry, requiring compliance with strict quality and safety standards.
  • Competition from larger companies with greater financial resources and broader networks.

Opportunities

Fusion Antibodies PLC has several opportunities to capitalize on:

  • Increasing demand for antibody-based therapies in the pharmaceutical industry.
  • Expanding into new geographic markets, particularly in emerging economies.
  • Collaborating with academic institutions and research organizations for new discoveries.
  • Exploring partnerships and licensing agreements to broaden the product portfolio.
  • Investing in research and development to stay ahead in antibody technology advancements.

Threats

Fusion Antibodies PLC faces various threats that could impact its business:

  • Intense competition from established players and new entrants in the antibody industry.
  • Changing regulatory landscape and evolving industry standards.
  • Economic downturns and market volatility affecting customer spending on research and development.
  • Potential disruptions to the supply chain and sourcing of raw materials.
  • Rapid technological advancements leading to obsolescence if not adequately adapted.

Fusion Antibodies Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Fusion Antibodies historical P/E ratio, EBIT, and P/S ratio.

Fusion Antibodies shares outstanding

The number of shares was Fusion Antibodies in 2023 — This indicates how many shares 26.015 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Fusion Antibodies earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Fusion Antibodies's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Fusion Antibodies’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Fusion Antibodies's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Fusion Antibodies.

Fusion Antibodies latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/20230 0  (-28.67 %)2023 Q4
1

Fusion Antibodies list of shareholders

%
Name
Stocks
Change
Date
6.70817 % Unicorn Asset Management Ltd.6,397,29003/7/2024
4.94566 % Amati Global Investors Limited4,716,4632,375,0003/7/2024
4.73238 % Rathbones Investment Management Limited4,513,062-19,2823/7/2024
3.35327 % Invest Northern Ireland3,197,865974,45011/3/2023
1.92050 % Clarendon Fund Managers Limited1,831,500011/3/2023
1.55657 % Octopus Investments Limited1,484,434-40,8246/12/2023
1.51180 % Gresham House Asset Management Limited1,441,7351,441,7356/12/2023
1.47059 % Canaccord Genuity Wealth Management1,402,43908/22/2022
1.46803 % Crescent Capital NI Limited1,400,00002/19/2024
1.21899 % Walsh (Colin J.)1,162,500562,5002/19/2024
1
2
3
4
5
...
7

Fusion Antibodies Executives and Management Board

Dr. Richard Buick46
Fusion Antibodies Chief Scientific Officer, Executive Director (since 2011)
Compensation 123,000
Dr. Simon Douglas63
Fusion Antibodies Non-Executive Chairman of the Board (since 2011)
Compensation 35,000
Mr. Colin Walsh66
Fusion Antibodies Non-Executive Director
Compensation 27,000
Ms. Sonya Ferguson51
Fusion Antibodies Senior Non-Executive Independent Director
Compensation 23,000
Dr. Matthew Baker51
Fusion Antibodies Non-Executive Independent Director
Compensation 2,000
1
2

Fusion Antibodies Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
BeiGene Stock
BeiGene
SupplierCustomer0,750,880,600,860,850,60
Canaccord Genuity Group Stock
Canaccord Genuity Group
SupplierCustomer0,620,570,650,870,560,01
Merck Stock
Merck
SupplierCustomer0,300,88-0,190,860,10-0,12
GW Vitek Stock
GW Vitek
SupplierCustomer0,220,880,250,71--
Moderna Stock
Moderna
SupplierCustomer0,100,80-0,370,810,710,14
Bayer Stock
Bayer
SupplierCustomer-0,060,73-0,50-0,83-0,78-0,57
Mitsubishi Chemical Hldgs Stock
Mitsubishi Chemical Hldgs
SupplierCustomer-0,190,010,390,740,760,08
Eurofins Scientific Stock
Eurofins Scientific
SupplierCustomer-0,320,92-0,220,750,600,09
Amgen Stock
Amgen
SupplierCustomer-0,370,56-0,50-0,75-0,34-0,01
Johnson & Johnson Stock
Johnson & Johnson
SupplierCustomer-0,49-0,24-0,62-0,67-0,52-0,21
1
2

Most common questions regarding Fusion Antibodies

What values and corporate philosophy does Fusion Antibodies represent?

Fusion Antibodies PLC represents a set of core values and a corporate philosophy that guide its operations. The company's values include innovation, quality, and collaboration. Fusion Antibodies PLC is committed to driving innovation in antibody discovery and development, delivering high-quality services and products to its clients. The company fosters a collaborative approach, working closely with partners and customers to achieve mutual success. Emphasizing integrity and ethical practices, Fusion Antibodies PLC maintains a customer-centric focus and seeks to continuously improve its operations and offerings. Through its values and corporate philosophy, Fusion Antibodies PLC strives to make a positive impact in the field of antibody research and healthcare.

In which countries and regions is Fusion Antibodies primarily present?

Fusion Antibodies PLC is primarily present in the United Kingdom and Ireland.

What significant milestones has the company Fusion Antibodies achieved?

Fusion Antibodies PLC, a leading biotechnology company, has achieved significant milestones in its journey. Notably, the company successfully listed on London's AIM market in December 2017, raising funds to expand its operations and pursue strategic growth opportunities. Furthermore, Fusion Antibodies has built a strong reputation as a specialist Contract Research Organization (CRO) with expertise in antibody engineering and development. The company has continuously advanced its proprietary antibody optimization platform, which enables the discovery and development of unique antibody therapeutics. Fusion Antibodies has also established several key partnerships and collaborations in the biopharmaceutical industry, reinforcing its position as a trusted, innovative player in the field.

What is the history and background of the company Fusion Antibodies?

Fusion Antibodies PLC is a biotechnology company specializing in the discovery and development of antibodies for pharmaceutical, diagnostic, and research purposes. Founded in 2001, Fusion Antibodies has established itself as a leader in antibody engineering and humanization, helping clients optimize their antibody candidates for therapeutic use. With a team of experienced scientists and state-of-the-art facilities, the company offers a range of services, including antibody production, cell line development, and antibody engineering. Fusion Antibodies PLC has formed strategic partnerships with renowned pharmaceutical companies, contributing to the advancement of novel therapies. With a strong history and track record, Fusion Antibodies PLC continues to drive innovation in the field of antibody therapeutics.

Who are the main competitors of Fusion Antibodies in the market?

Some of the main competitors of Fusion Antibodies PLC in the market include Abcam PLC, GenScript Biotech Corporation, and Abzena PLC.

In which industries is Fusion Antibodies primarily active?

Fusion Antibodies PLC is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Fusion Antibodies?

The business model of Fusion Antibodies PLC revolves around providing advanced antibody discovery, engineering, and manufacturing services to pharmaceutical and biotechnology companies. Fusion Antibodies specializes in the development of antibodies for use in areas such as oncology, infectious diseases, and immuno-oncology. Their services include antibody humanization, antibody library generation, antibody engineering, and antibody manufacturing. Fusion Antibodies collaborates with clients to create custom solutions and optimize therapeutic antibody development. With their expertise in antibody technologies, Fusion Antibodies aims to support the development of novel drugs and therapies by delivering high-quality, cost-effective antibody products.

What is the P/E ratio of Fusion Antibodies 2024?

The P/E ratio cannot be calculated for Fusion Antibodies at the moment.

What is the P/S ratio of Fusion Antibodies 2024?

The P/S cannot be calculated for Fusion Antibodies currently.

What is the AlleAktien quality score of Fusion Antibodies?

The AlleAktien quality score for Fusion Antibodies is 2/10.

What is the revenue of Fusion Antibodies 2024?

The revenue cannot currently be calculated for Fusion Antibodies.

How high is the profit of Fusion Antibodies 2024?

The profit cannot currently be calculated for Fusion Antibodies.

What is the business model of Fusion Antibodies

The company Fusion Antibodies PLC is a leading provider of antibody solutions and services on a global level. The company offers its customers access to a wide range of high-quality antibodies, proteins, and reagents, from antibody provision to services such as antibody development, manufacturing, and characterization. Fusion Antibodies PLC specializes in providing innovative and customized antibody solutions. The company has developed a wide range of antibody products that can be used in various applications, including custom antibodies to support research and development, as well as therapeutic antibodies for disease diagnosis and treatment. The company has extensive experience in antibody manufacturing and offers various services to support product development, including antibody purification and characterization, monoclonal antibody production, and antibody conjugate production for drug development. Fusion Antibodies PLC has also developed some new services that contribute to increasing productivity and shortening product development time. These include antibody cloning, antibody optimization, and antibody-protein fusion technology. These services are offered to meet the needs of both pharmaceutical companies and companies in the field of biotechnological research. The company has a wide range of manual and automated laboratory services and works closely with its customers to meet their specific requirements. This collaboration helps significantly accelerate research and development processes. Among all the offerings of Fusion Antibodies PLC, its innovative Fusion Express platform stands out. This technology enables faster and more efficient antibody development by incorporating antibodies into specialized expression systems. Fusion Antibodies PLC has also announced the acquisition of Innovate Biopharmaceuticals, Inc. - a company focused on developing new therapies for inflammatory diseases. Overall, Fusion Antibodies PLC offers its customers a comprehensive range of services and products for antibody development. The company is committed to always offering innovative solutions to meet the growing demand for product development. With its specialized laboratory services and experienced team of scientists and technicians that consider customer requirements, Fusion Antibodies PLC is a valuable resource for pharmaceutical companies, biotechnology companies, and research laboratories worldwide.

What is the Fusion Antibodies dividend?

Fusion Antibodies pays a dividend of 0 GBP distributed over payouts per year.

How often does Fusion Antibodies pay dividends?

The dividend cannot currently be calculated for Fusion Antibodies or the company does not pay out a dividend.

What is the Fusion Antibodies ISIN?

The ISIN of Fusion Antibodies is GB00BDQZGK16.

What is the Fusion Antibodies ticker?

The ticker of Fusion Antibodies is FAB.L.

How much dividend does Fusion Antibodies pay?

Over the past 12 months, Fusion Antibodies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Fusion Antibodies is expected to pay a dividend of 0 GBP.

What is the dividend yield of Fusion Antibodies?

The current dividend yield of Fusion Antibodies is .

When does Fusion Antibodies pay dividends?

Fusion Antibodies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Fusion Antibodies?

Fusion Antibodies paid dividends every year for the past 0 years.

What is the dividend of Fusion Antibodies?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Fusion Antibodies located?

Fusion Antibodies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Fusion Antibodies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Fusion Antibodies from 9/9/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.

When did Fusion Antibodies pay the last dividend?

The last dividend was paid out on 9/9/2024.

What was the dividend of Fusion Antibodies in the year 2023?

In the year 2023, Fusion Antibodies distributed 0 GBP as dividends.

In which currency does Fusion Antibodies pay out the dividend?

The dividends of Fusion Antibodies are distributed in GBP.

All fundamentals about Fusion Antibodies

Our stock analysis for Fusion Antibodies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fusion Antibodies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.